Gene targets of antisense therapies in breast cancer

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 3, 2002, Pages 375-385

  Yang, Ding Cheng ^a   Elliott, Robert L ^a   Head, Jonathan F ^a  

^a The Mastology Research Institute   (United States)

Author keywords

Antisense oligonucleotides; Antisense RNA; Breast cancer; Drug delivery systems; Gene targets

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BRCA PROTEIN; COMPLEMENTARY RNA; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; FERRITIN; HEAT SHOCK PROTEIN 27; LIPOSOME; MESSENGER RNA; METALLOTHIONEIN; MULTIDRUG RESISTANCE PROTEIN; OLIGONUCLEOTIDE; ONCOPROTEIN; PARVOVIRUS VECTOR; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN MDM2; PROTEIN P12; RETROVIRUS VECTOR; SOMATOMEDIN C RECEPTOR; TRANSFERRIN RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INVASION; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG SENSITIVITY; FEASIBILITY STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; HOST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRON RESPONSIVE ELEMENT; METASTASIS; NONHUMAN; ONCOGENE; ONCOGENE C FOS; ONCOGENE C MYC; ONCOGENE C RAF; ONCOGENE NEU; RADIOSENSITIVITY; REVIEW; RNA DEGRADATION; SIDE EFFECT; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTISENSE ELEMENTS (GENETICS); APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CLINICAL TRIALS; DRUG CARRIERS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; IRON; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES; RNA PRECURSORS; RNA, NEOPLASM; RNA, SMALL NUCLEAR; TRANSFECTION;

EID: 0036075079     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.3.375     Document Type: Review

References (67)

1. Molecular analysis of premalignant and carcinoma in situ lesions of the human breast
2. Nuclear oncogenes in breast cancer
3. Molecular epidemiology of breast cancer
4. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
5. Prognostic value of c-erbB2 expression in breast cancer
6. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer
7. HER2/neu antisense targeting of human breast carcinoma
8. Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells
9. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration
10. Growth inhibition and antimetastatic effect of antisense poly-DNP-RNA on human breast cancer cells
11. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A
12. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides
13. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA
14. Biodistribution of iodine-125 tyramine transforming growth factor alpha antisense oligonucleotide in athymic mice with a human mammary tumour xenograft following intratumoral injection
15. Comparative analysis of IFN-γ B7.1 and antisense TGF-β gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol
16. Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-βI
17. Expression of an antisense transforming growth factor-β1 transgene reduces tumorigenicity of EMT6 mammary tumor cells
18. Treatment of human breast cancer cells with antisense RNA to the Type 1 insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo
19. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation
20. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth Factor I receptor antisense ribonucleic acid
21. Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21 (WAF1)
22. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: In vitro and in vivo activities and mechanisms
23. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II)
24. Activity of a novel Bcl-2/Bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins
25. Genasense (Genta Inc)
26. Induction of PCD in tamoxifen-resistant estrogen receptor positive (ER+) advanced breast cancer after combined therapy with ER antisense oligonucleotides and vinorelbine-tartrate encapsulated in DRV liposomes
27. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF
28. Multidrug resistance in cancer: Role of ATP dependent transporters
29. Concerning antisense inhibition of the multiple drug resistance gene
30. Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: Evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells
31. Liposomal delivery of antisense oligodeoxynucleotides. Application to the inhibition of the multidrug resistance in cancer cells
32. Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells
33. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer
34. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide target to the transferring receptor gene
35. Inhibition of growth of human breast carcinoma cells by antisense oligonucleotides targeted to the ferritin genes
36. Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression
37. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice
38. Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA
39. Antisense inhibition of the 27 kDa heat shock protein production affects growth rate and cytoskeletal organization in MCF-7 cells
40. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subscutaneously into nude mice
41. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer
42. Antisense cancer therapy: The state of the science
43. Oligonucleotide therapeutics: Clothing the emperor
44. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells
45. The use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genes
46. Phenocopy of discoidin I-minus mutants by antisense transformation in Dictyostelium
47. Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues
48. Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides
49. Sequence-specific cleavage of double helical DNA by triple helix formation
50. Sequence-specific artificial photo-induced endonucleases based on triple helix-forming oligonucleotides
51. Temporary ex vivo inhibition of the expression of the human oncogene HER-2 (NEU) by a triple helix-forming oligonucleotide
52. Oligodeoxynucleotides covalently linked to intercalating agents: A new class of gene regulatory substances
53. Interactions between single-stranded DNA binding protein and oligonucleotide analogs with different backbone chemistries
54. Perturbing gene expression with oligodeoxynucleotides: Research and potential therapeutic applications
55. Inhibition of DNA synthesis by cross-linking the template to platinum-thiol derivatives of complementary oligodeoxynucleotides
56. The synthesis and biological activities of oligodeoxynucleotides that are covalently linked to psoralen at their 5′ ends
57. Site-specific cleavage of single-stranded and double-stranded DNA sequences by oligodeoxynucleotides covalently linked to an intercalating agent and EDTA-Fe chelate
58. Generation of a catalytic sequence-specific hybrid DNase
59. A hammerhead ribozyme suppress expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells
60. Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA
61. Adenovirus-mediated ribozyme targeting of HER2/neu inhibits in vivo growth of breast cancer cells
62. Efficient gene transfer into nondividing cells by adeno-associated virus-bases vectors
63. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
64. Electroporation of synthetic oligonucleotides: A novel technique for ex vivo bone marrow purging
65. Synthetic oligonucleotides: The development of antisense therapeutics
66. Antisense therapeutics: Lessons from early clinical trials
67. Antisense oligonucleotides in cutaneous therapy